Company Encyclopedia
View More
name
Inogen
INGN.US
Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One and Inogen Rove, an ambulatory solutions for long-term oxygen therapy; Rove 4, a portable oxygen concentrator; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories. It also rents its products directly to patients.
1.392 T
INGN.USMarket value -Rank by Market Cap -/-

Financial Score

26/12/2025 Update
C
Health Care EquipmentIndustry
Industry Ranking77/174
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-13.27%D
    • Profit Margin-7.31%D
    • Gross Margin44.72%B
  • Growth ScoreC
    • Revenue YoY4.68%C
    • Net Profit YoY51.83%B
    • Total Assets YoY0.27%C
    • Net Assets YoY6.35%B
  • Cash ScoreD
    • Cash Flow Margin-1367.49%E
    • OCF YoY4.68%C
  • Operating ScoreA
    • Turnover1.13A
  • Debt ScoreB
    • Gearing Ratio35.78%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    CEO Smith Acquires 14,517 Of Inogen Inc [INGN]

    CEO Smith of Inogen Inc acquired 14,517 shares, filed under Form 4 with the SEC. The transaction included exercising 28,334 shares and surrendering 13,817 shares at $6.95 each to cover option exercise costs and tax liabilities. Ending holdings are 86,291 shares directly. The Washington Service offers insider trading analysis and data services.

    Reuters·
    US
    INGN
    -0.15%
    Reuters·
    US
    INGN
    -0.15%

    Inogen Inc. Publishes Transcript of Q3 2025 Earnings Call

    Inogen Inc. has released the transcript of its Q3 2025 earnings call, held on November 5, 2025. Key leaders, including CEO Kevin R.M. Smith and CFO Michael J. Bourque, discussed the company's financial results, growth prospects, and commitment to improving respiratory patient lives. The management expressed pride in the company's momentum and optimism for future opportunities. The full transcript is available online.

    Reuters·
    US
    INGN
    -0.15%
    Reuters·
    US
    INGN
    -0.15%

    Inogen Inc’s Earnings Call: Growth Amid Challenges

    Inogen Inc's Q3 earnings call highlighted consistent revenue growth of over $92 million, driven by a 15% increase in unit sales and a 19% rise in international B2B performance. The company achieved adjusted EBITDA profitability of $2.3 million and positive operating cash flow of $2.2 million. However, it faced challenges with a 17.9% decline in direct-to-consumer sales and a 4.4% drop in rental revenue. Despite these hurdles, Inogen remains on track for full-year revenue guidance of $354 million to $357 million, focusing on innovation and market expansion.

    Tip Ranks·
    US
    INGN
    -0.15%
    Tip Ranks·
    US
    INGN
    -0.15%

    Inogen | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 92.39 M

    LB filings·
    US
    INGN
    -0.15%
    LB filings·
    US
    INGN
    -0.15%

    Inogen’s Strong Q3 Performance and Promising Growth Potential Earns Buy Rating

    Inogen has received a Buy rating from Michael Matson following a strong Q3 performance, with revenue and adjusted EBITDA exceeding expectations. The company saw robust B2B sales, despite lower DTC sales, and launched the Voxi 5 stationary oxygen concentrator. Inogen has achieved mid-single-digit revenue growth and anticipates 9-12% growth in Q4 2025, indicating a positive outlook and potential for further improvement.

    Tip Ranks·
    US
    INGN
    -0.15%
    Tip Ranks·
    US
    INGN
    -0.15%
    © 2025 Longbridge｜Disclaimer